COMPANY PROFILE

Prokarium

Explore full profile

Oral vaccines for infectious diseases

London, United KingdomFounded 2012Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Prokarium

Prokarium is a biopharmaceutical company that is a leader in the oncology field of microbial immunotherapy. The company's pipeline is designed to advance immuno-oncology by building on the most recent advances in the field. Prokarium's lead program is currently in clinical trials for bladder cancer.

Read full description

Prokarium's mission is to create novel cancer treatments by applying synthetic biology. The company is also developing oral and thermostable vaccines against Chlamydia trachomatis, a sexually transmitted infection.

Prokarium's business model is focused on the development and commercialization of its proprietary technology platform. The company's target clients are patients with cancer and other diseases that can be treated with microbial immunotherapy.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: London, United Kingdom
Employees: 18
Open positions: None listed
Dealroom signal: 72.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Vaccines, Genetics and genomics, Immune System, Synthetic Biology, Biotech and Pharma, BIA Techbio UK, Techbio
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
CONVERTIBLEOther financing	Dec 2025	$6.3M	—	Flerie Invest	↗
GRANTOther financing	Aug 2024	$419K	—	UK Research and Innovation	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Prokarium website traffic

Latest recorded traffic for Prokarium is 1.1K monthly website visits, up 340% over the last three months. Prokarium's team grew 0% over the past year.

Latest monthly visits1.1K 3-month web change+340% 1-year team growth0%

Monthly website visitsMar 2017–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TGTouchlight GeneticsDevelops a DNA production platform designed for the development of DNA vaccines for oncology and infectious diseases	London, United Kingdom	Operational	161	$125M	$1B
SBSphere BioEnabling rapid screening and characterisation of single cells	Cambridge, United Kingdom	Operational
NUNucleraMaking biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day	Cambridge, United Kingdom	Operational
EVEvonetixUr desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible	Cambridge, United Kingdom	Operational
BABactobioLondon-based biotechnology company using breakthrough technologies in synthetic biology	London, United Kingdom	Operational
BIbit.bioDeveloping a scalable technology platform capable of producing consistent batches of every human cell	Cambridge, United Kingdom	Operational
LALabGeniusCombining human and machine intelligence to accelerate the discovery of advanced medicines	London, United Kingdom	Operational
COcoding.bioBuilding best-in-class cell therapies through automation and computation	Oxford, United Kingdom	Operational